1148 related articles for article (PubMed ID: 15655528)
21. Comparison of three radioligands for the labelling of human beta-adrenoceptor subtypes.
Niclauss N; Michel-Reher MB; Alewijnse AE; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):99-105. PubMed ID: 17028849
[TBL] [Abstract][Full Text] [Related]
22. Site of action of beta-ligands at the human beta1-adrenoceptor.
Baker JG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1163-71. PubMed ID: 15716385
[TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Hoffmann C; Leitz MR; Oberdorf-Maass S; Lohse MJ; Klotz KN
Naunyn Schmiedebergs Arch Pharmacol; 2004 Feb; 369(2):151-9. PubMed ID: 14730417
[TBL] [Abstract][Full Text] [Related]
24. Characterization of beta 1- and beta 3-adrenoceptors in intact brown adipocytes of the rat.
D'Allaire F; Atgié C; Mauriège P; Simard PM; Bukowiecki LJ
Br J Pharmacol; 1995 Jan; 114(2):275-82. PubMed ID: 7881727
[TBL] [Abstract][Full Text] [Related]
25. Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.
Kaumann AJ; Engelhardt S; Hein L; Molenaar P; Lohse M
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):87-93. PubMed ID: 11191841
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the binding affinity of some newly synthesized phenylethanolamine and phenoxypropanolamine compounds at recombinant human beta- and alpha1-adrenoceptor subtypes.
Ahmed M; Hanaoka Y; Kiso T; Kakita T; Ohtsubo Y; Muramatsu I; Nagatomo T
J Pharm Pharmacol; 2005 Jan; 57(1):75-81. PubMed ID: 15638996
[TBL] [Abstract][Full Text] [Related]
27. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome.
Masunaga K; Chapple CR; McKay NG; Yoshida M; Sellers DJ
Neurourol Urodyn; 2010 Sep; 29(7):1320-5. PubMed ID: 20151470
[TBL] [Abstract][Full Text] [Related]
28. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.
Tyagi P; Thomas CA; Yoshimura N; Chancellor MB
Int Braz J Urol; 2009; 35(1):76-83. PubMed ID: 19254402
[TBL] [Abstract][Full Text] [Related]
29. beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue.
Konkar AA; Zhai Y; Granneman JG
Mol Pharmacol; 2000 Feb; 57(2):252-8. PubMed ID: 10648634
[TBL] [Abstract][Full Text] [Related]
30. The effects and selectivity of beta-adrenoceptor agonists in rat myometrium and urinary bladder.
Clouse AK; Riedel E; Hieble JP; Westfall TD
Eur J Pharmacol; 2007 Nov; 573(1-3):184-9. PubMed ID: 17632099
[TBL] [Abstract][Full Text] [Related]
31. Molecular and functional characteristics of β3-adrenoceptors in late pregnant mouse uterus: a comparison with β2-adrenoceptors.
Parida S; Uttam Singh T; Ravi Prakash V; Mishra SK
Eur J Pharmacol; 2013 Jan; 700(1-3):74-9. PubMed ID: 23219791
[TBL] [Abstract][Full Text] [Related]
32. Divergent agonist selectivity in activating β1- and β2-adrenoceptors for G-protein and arrestin coupling.
Casella I; Ambrosio C; Grò MC; Molinari P; Costa T
Biochem J; 2011 Aug; 438(1):191-202. PubMed ID: 21561432
[TBL] [Abstract][Full Text] [Related]
33. beta1- and beta2-adrenoceptor induced synaptic facilitation in rat basolateral amygdala.
Abraham PA; Xing G; Zhang L; Yu EZ; Post R; Gamble EH; Li H
Brain Res; 2008 May; 1209():65-73. PubMed ID: 18396264
[TBL] [Abstract][Full Text] [Related]
34. Effect of β
Saunders SL; Hutchinson DS; Britton FC; Liu L; Markus I; Sandow SL; Murphy TV
Br J Pharmacol; 2021 Apr; 178(8):1789-1804. PubMed ID: 33506492
[TBL] [Abstract][Full Text] [Related]
35. Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
Molenaar P; Sarsero D; Arch JR; Kelly J; Henson SM; Kaumann AJ
Br J Pharmacol; 1997 Jan; 120(2):165-76. PubMed ID: 9117106
[TBL] [Abstract][Full Text] [Related]
36. β
Cook RF; Bussey CT; Fomison-Nurse IC; Hughes G; Bahn A; Cragg PA; Lamberts RR
Exp Physiol; 2019 Jun; 104(6):808-818. PubMed ID: 30889297
[TBL] [Abstract][Full Text] [Related]
37. Role of beta-adrenergic receptor subtypes in lipolysis.
Louis SN; Jackman GP; Nero TL; Iakovidis D; Louis WJ
Cardiovasc Drugs Ther; 2000 Dec; 14(6):565-77. PubMed ID: 11300357
[TBL] [Abstract][Full Text] [Related]
38. Role of beta1-, beta2-, and beta3-adrenoceptors in contractile hypersensitivity in a model of small bowel transplantation.
Rickenbacher A; Seiler R; Honegger U; Shaw SG; Balsiger BM
Surgery; 2008 Jan; 143(1):94-102. PubMed ID: 18154937
[TBL] [Abstract][Full Text] [Related]
39. Effects of milrinone on contractility and cyclic adenosine monophosphate production induced by beta1- and beta2-adrenergic receptor activation in human myocardium.
Carceles MD; Fuentes T; Aroca V; Lopez J; Hernández J
Clin Ther; 2007 Aug; 29(8):1718-24. PubMed ID: 17919552
[TBL] [Abstract][Full Text] [Related]
40. The odd sibling: features of β3-adrenoceptor pharmacology.
Cernecka H; Sand C; Michel MC
Mol Pharmacol; 2014 Nov; 86(5):479-84. PubMed ID: 24890609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
